Rade N Pejic1. 1. Department of Family Medicine, Tulane University School of Medicine, New Orleans, LA.
Abstract
BACKGROUND: Familial hypercholesterolemia (FH) is an autosomal dominant-inherited genetic disorder that leads to elevated blood cholesterol levels. FH may present as severely elevated total cholesterol and low density lipoprotein (LDL) cholesterol levels or as premature coronary heart disease (CHD). METHODS: This review presents information on the disease and on the effects of drug treatment and lifestyle changes. RESULTS: Routine lipid testing should identify most patients with FH. Once an index case is identified, testing should be offered to family members. Early diagnosis and aggressive treatment with therapeutic lifestyle changes and statins can prevent premature CHD and other atherosclerotic sequelae in patients with FH. CONCLUSION: Emerging therapies such as LDL apheresis and novel therapeutic agents may be useful in patients with homozygous FH or treatment-resistant FH. Liver transplantation is the only effective therapy for severe cases of homozygous FH.
BACKGROUND:Familial hypercholesterolemia (FH) is an autosomal dominant-inherited genetic disorder that leads to elevated blood cholesterol levels. FH may present as severely elevated total cholesterol and low density lipoprotein (LDL) cholesterol levels or as premature coronary heart disease (CHD). METHODS: This review presents information on the disease and on the effects of drug treatment and lifestyle changes. RESULTS: Routine lipid testing should identify most patients with FH. Once an index case is identified, testing should be offered to family members. Early diagnosis and aggressive treatment with therapeutic lifestyle changes and statins can prevent premature CHD and other atherosclerotic sequelae in patients with FH. CONCLUSION: Emerging therapies such as LDL apheresis and novel therapeutic agents may be useful in patients with homozygous FH or treatment-resistant FH. Liver transplantation is the only effective therapy for severe cases of homozygous FH.
Entities:
Keywords:
Genetic diseases–inborn; hypercholesterolemia; hyperlipoproteinemia type II
Authors: Neil J Stone; Jennifer G Robinson; Alice H Lichtenstein; C Noel Bairey Merz; Conrad B Blum; Robert H Eckel; Anne C Goldberg; David Gordon; Daniel Levy; Donald M Lloyd-Jones; Patrick McBride; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Karol Watson; Peter W F Wilson; Karen M Eddleman; Nicole M Jarrett; Ken LaBresh; Lev Nevo; Janusz Wnek; Jeffrey L Anderson; Jonathan L Halperin; Nancy M Albert; Biykem Bozkurt; Ralph G Brindis; Lesley H Curtis; David DeMets; Judith S Hochman; Richard J Kovacs; E Magnus Ohman; Susan J Pressler; Frank W Sellke; Win-Kuang Shen; Sidney C Smith; Gordon F Tomaselli Journal: Circulation Date: 2013-11-12 Impact factor: 29.690
Authors: Dirk J Blom; Tomas Hala; Michael Bolognese; Michael J Lillestol; Phillip D Toth; Lesley Burgess; Richard Ceska; Eli Roth; Michael J Koren; Christie M Ballantyne; Maria Laura Monsalvo; Kate Tsirtsonis; Jae B Kim; Rob Scott; Scott M Wasserman; Evan A Stein Journal: N Engl J Med Date: 2014-03-29 Impact factor: 91.245
Authors: Alice H Lichtenstein; Lynne M Ausman; Susan M Jalbert; Montserrat Vilella-Bach; Matti Jauhiainen; Sandra McGladdery; Arja T Erkkilä; Christian Ehnholm; Jiri Frohlich; Ernst J Schaefer Journal: J Lipid Res Date: 2002-02 Impact factor: 5.922
Authors: Eli M Roth; Marja-Riitta Taskinen; Henry N Ginsberg; John J P Kastelein; Helen M Colhoun; Jennifer G Robinson; Laurence Merlet; Robert Pordy; Marie T Baccara-Dinet Journal: Int J Cardiol Date: 2014-07-02 Impact factor: 4.164
Authors: Alpo Vuorio; Jaana Kuoppala; Petri T Kovanen; Steve E Humphries; Serena Tonstad; Albert Wiegman; Euridiki Drogari Journal: Cochrane Database Syst Rev Date: 2014-07-23